Board appointments at QBiotics Group

Brisbane, 20 May 2024

QBiotics Group Limited (QBiotics) is pleased to announce the appointment of two Non-executive Directors to its Board with effect from 20 May 2024.

Mark Fladrich is an experienced pharmaceutical executive with more than 30 years’ in the industry, including 23 years with AstraZeneca. Mark brings to QBiotics a wealth of knowledge and experience in global commercial strategy and implementation across all phases of the pharmaceutical product lifecycle. Mark held various senior roles during his time with AstraZeneca including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe.

David Phillips brings to QBiotics more than 40 years’ experience in the healthcare industry, 23 of which were with Glaxo Wellcome (now GlaxoSmithKline (GSK)). He was the Managing Partner in the corporate venture arm of GSK where he spun out new technologies from across the business. David has been responsible for capital raisings globally, as well as the execution of over 50 pharmaceutical and biotechnology deals. David was previously a director on the board of Suda Pharmaceuticals (now Arovella Therapeutics Limited ASX:ALA) and is currently Non-Executive Chair for Inosi Therapeutics.

QBiotics’ Executive Chair, Dr. Susan Foden said of the appointments, “On behalf of my fellow directors, I welcome Mark Fladrich and David Phillips to the Board of QBiotics. As part of our ongoing Board renewal and succession plan, we are very fortunate to have secured directors with deep experience across the full pharmaceutical development, commercalisation and deal-making chain. I look forward to working with Mark and David and to the knowledge, networks and capabilities they will bring to the Board.”

We acknowledge the assistance and support of Coulter Partners in facilitating the appointments.



JANE LOWE, IR DEPARTMENT  +61 411 117 774



QBiotics is an unlisted public Australian life sciences company that speacilises in the discovery and development of novel cell signalling small molecules. QBiotics applies phenotypic screening to generate breakthrough innovation in the discovery of first in class solutions to challenging medical conditions. Our current clinical focus is on novel treatments for cancer and debilitating chronic wounds.

QBiotics’ lead oncology drug, tigilanol tiglate, is a small molecule targeting a range of solid tumours and is currently in human clinical Phase II development. A veterinary formulation of tigilanol tiglate is registered and marketed as an oncology pharmaceutical, under the trade name STELFONTA®, in the USA, Europe, the UK and Australia.

QBiotics’ lead wound healing drug candidate is a small molecule targeting a range of wounds including chronic and acute wounds and burns. Preparation is in progress for a first-in-human Phase I/IIa clinical trial in patients with venous leg ulcers.